Inverse pityriasis rosea secondary to COVID-19 vaccination.
COVID-19
pityriasis rosea
vaccination
Journal
Proceedings (Baylor University. Medical Center)
ISSN: 0899-8280
Titre abrégé: Proc (Bayl Univ Med Cent)
Pays: United States
ID NLM: 9302033
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
A 56-year-old woman presented for evaluation of a pruritic rash with associated body aches, fever, and chills that first appeared about 1 week after Johnson and Johnson COVID-19 vaccination. The rash initially presented as one lesion on her left breast that then spread to her face and groin. Based on clinical presentation, dermoscopic findings, and histopathological examination, a diagnosis of inverse pityriasis rosea was made. Although the exact pathogenesis of pityriasis rosea remains unknown, current evidence suggests that the inflammatory reaction to infectious agents, vaccines, certain drugs, or reactivation of herpesvirus 6 and 7 are possible etiologies.
Identifiants
pubmed: 35518792
doi: 10.1080/08998280.2022.2044742
pii: 2044742
pmc: PMC9037553
doi:
Types de publication
Case Reports
Langues
eng
Pagination
342-343Informations de copyright
Copyright © 2022 Baylor University Medical Center.
Références
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e489-e491
pubmed: 33899974
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):544-5
pubmed: 25545307
Dermatol Ther. 2021 Nov;34(6):e15129
pubmed: 34533265
Am Fam Physician. 2004 Jan 1;69(1):87-91
pubmed: 14727822
Br J Dermatol. 2021 Jun;184(6):1194-1195
pubmed: 33511657
Dermatol Online J. 2017 Feb 15;23(2):
pubmed: 28329497
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Indian J Dermatol. 2016 Jul-Aug;61(4):375-84
pubmed: 27512182
Am Fam Physician. 2018 Jan 1;97(1):38-44
pubmed: 29365241
Int J Dermatol. 2021 Sep;60(9):1150-1151
pubmed: 34110010